RBC Capital Reiterates Outperform on Xenon Pharmaceuticals, Maintains $51 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has reiterated his 'Outperform' rating on Xenon Pharmaceuticals (NASDAQ:XENE) and maintained a price target of $51.
September 22, 2023 | 2:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital's reiteration of an 'Outperform' rating and a $51 price target for Xenon Pharmaceuticals could positively influence the company's stock in the short term.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. In this case, RBC Capital's reiteration of an 'Outperform' rating and a $51 price target for Xenon Pharmaceuticals indicates a positive outlook for the company, which could lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100